Investor Presentation

GUJARAT THEMIS BIOSYN LIMITED CIN: L24230GJ1981PLC004878 REGD. OFFICE &FACTORY: 69/C GIDC INDUSTRIAL ESTATE, VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA TEL: 0260-2430027 / 2400639 E-mail:hrm@gtbl.in.net GTBL/BSE/NSE/2026-27/33 29th June, 2026 Corporate Relationship Department Listing Department BSE Limited National Stock Exchange of India Limited Floor 25, Phiroze Jeejeebhoy Towers Exchange Plaza, Dalal Street, Mumbai- 400001 Bandra Kurla Complex, Scrip Code – 506879 Bandra (East), Mumbai- 400051 Symbol: GUJTHEM Dear Sir / Madam, Sub: Investor Presentation In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), we submit herewith the Investors’ Presentation of the Gujarat Themis Biosyn Limited (‘the Company’). Further, a copy of the same is also available on the website of the Company at http://www.gtbl.in Kindly take the same on record and acknowledge receipt of the same. Thanking you, Yours faithfully, For Gujarat Themis Biosyn Limited Vineet Gawankar Company Secretary and Compliance Officer Place: Mumbai MUMBAI OFFICE: Themis House, 11/12 Udyog Nagar, S.V Road, Goregaon (West), Mumbai – 400 104 Tel: 91-22-67607080 / 28757836 Fax: 28746621 / 67607019; E-mail: gtblmumbai@gtbl.in Website Address: www.gtbl.in Gujarat Themis Biosyn Limited Roadshow Presentation June 2026 Click tGol oesdsaitr yMaster title style Abbreviations Abbreviations ADC Antibody Drug Conjugation FY Financial Year (1st April – 31st March) API Active Pharmaceutical Ingredient GIIC Ltd. Gujarat Industrial Investment Corporation Limited CDMO Contract Development and Manufacturing Organization GMP Good Manufacturing Practice Crs Crores GTBL Gujarat Themis Biosyn Limited CY Calendar Year (1st January – 31st December) JPY Japanese Yen DNA Deoxyribonucleic acid KL Kilo Litres EBIT Earnings before interest and tax MEA Middle East and Africa Earnings before interest, tax, depreciation and EBITDA PAT Profit after tax amortisation ESG Environmental, Social, and Governance PMDA Pharmaceuticals and Medical Devices Agency FDA Food and Drug Administration R&D Research and Development FDF Finished Dosage Forms WHO World Health Organization Click tGoT eBLd oitn M Traacskt etor btietcleom stey al eDiversified Pharma Platform Enhancing Fermentation Capabilities Forward Integration Gujarat Themis Biosyn Limited Acquisition of Sanofi’s Select Acquisition of MicroBiopharm Japan(1) Product Portfolio(1) Product Portfolio Expansion of Technical Product Portfolio Expansion Expansion Capabilities ▪ Immunosuppressants ▪ Peptides Fermentation ▪ Plasmids Ownership of 13 tuberculosis and anti-infective brands ▪ Oncology Fermentation ▪ ADCs ▪ Specializes in fermentation-based sales, primarily across MEA and Europe intermediates and APIs(2) ▪ Anti-Infectives ▪ Enzyme Engineering ▪ Intermediates – Rifa-based intermediates, ▪ Product Portfolio – Anti-TB and Anti-Infectives ▪ One manufacturing facility in Valsad, Gujarat ▪ CDMO – Pharma, Non-Pharma, Biologics ▪ Capacity – 990 KL ▪ Products – Rifa-based 13 tuberculosis and anti-infective generic brands ▪ Markets – Asia, Japan and Europe ▪ Major Markets – Middle East & Africa and Europe, with ▪ Plants – 3 in Japan strong retail channel presence Note: (1) Acquisitions are subject to regulatory approvals; (2) APIs are not yet launched and are in the testing phase Gujarat Themis Biosyn Limited Click tGoT eBLd -i tS nMapasshtoetr title style 1 Product Portfolio Key Highlights Intermediate for Anti-Tuberculosis t a a f Used for manufacturing drug Rifampicin i d iR (Antibiotic used for treatment of bacterial infections, including tuberculosis) 1 990 KL 235 Manufacturing Site Annual Capacity Employee Strength n Intermediate for Anti-Infectives Used for manufacturing drug Rifaximin, a 1 45.55% GMP iR Used for gastrointestinal therapeutic areas (Antibiotic used as anti-infective) R&D Lab EBITDA Margin (FY26) Manufacturing Site In FY26, Company successfully completed forward integration in 3 R&D Capabilities Active Pharmaceutical Ingredients New R&D lab established within existing facility in Valsad, Gujarat, foraying R&D 2 Fermentation-based Manufacturing program towards developing new intermediate molecules and exploring additional applications for existing ones Capacity (KL) Annual fermentation capacity doubled; Ventured into API production as part of forward 990.00 integration strategy 450.00 R&D Facility has a GMP(1) approval FY25 FY26 Note: (1) Good Manufacturing Practices Click tGor oewdtiht MDriavsetres r title style R&D Driven Innovation & Forward Integration New Infrastructure Development Strategic ESG & Cost optimization initiative Geographical Diversification Enhance Capacity to meet future growth Click tFoin eadncitia Mls aster title style Revenue from Operations (INR Lakhs) EBITDA(1) (INR Lakhs) and EBITDA Margin 16,982.19 16,582.28 46.36% 45.65% 45.55% 15,079.99 7,873.37 7,553.02 6,884.44 FY24 FY25 FY26 FY24 FY25 FY26 PAT (INR Lakhs) and PAT Margins Return on Capital Employed(2) and Return on Equity(3) ROCE ROE 34.84% 32.34% 28.15% 39.40% 5,916.32 4,877.17 4,668.15 29.40% 23.60% 19.60% 16.20% 14.50% FY24 FY25 FY26 FY24 FY25 FY26 Note: (1) EBITDA excludes other income; (2) Return on Capital Employed = EBIT/(Shareholders Fund + Total Debt - non-current investments); (3) Return on Equity = Net Profit/Net Worth 7 Announced acquisition of Acquisition of MicroBiopharm Japan Note: Acquisition is subject to regulatory approvals Click tMo iecrdoiBti oMphaasrtmer J atpitalne Csoty. Lletd. – At a Glance and Strategic Rationale Key Highlights Fermentation h Microbial fermentation, large scale fermentation JPY 9.5 Bn n Customer Relationships 60+ 3 Plants e t Average business relationship of over 25 years with top 5 customers (INR 561.82 Crs) S Years of experience GMP-Compliant, with FDA & e Technology Platforms PMDA Approval Track Record FY26 Revenue Plasmid DNA, ADC Conjugation and P450 enzyme library Products Accelerates GTBL's Transition Towards Fermentation-based Globally Integrated CDMO Fermentation based Fermentation based Oncology APIs Anti-Infectives Immunosuppressants Used to prevent organ-transplant rejection API used in the treatment of breast cancer, Manufacturing of Anti-biotics (Josamycin) and in the treatment of certain cancers bladder cancer, leukemia, & other Malignancies Moving up the pharma value chain from Anti-Tuberculosis & Anti-Infective APIs to Specialty Small Molecules, Capabilities Biologics & Gene Therapy, leveraging proprietary fermentation expertise Peptides Plasmids Antibody Drug Conjugates (ADCs) Enzyme Engineering Microorganisms are engineered to Differentiated by proprietary technologies Two-step ADC synthesis via patented Designing high yielding strains using produce precise, high-value peptides spanning plasmid manufacturing, all-in- enzyme technology — site-specific and genome editing and enzyme engineering one plasmids, and platform methods homogeneous Note: INR/JPY– 0.59 (Source: www.rbi.org.in) 9 Click tSoy needrgitie Ms &a sVtaelur et iCtrleea stitoynle 1 Enhanced Fermentation & Precision Biotech Capabilities 2 Expanded Product Portfolio & Therapeutic Coverage 3 CDMO Platform 4 Entry into Advanced Biologics & Novel Modalities 5 Access to Established Relationships with Pharmaceutical Companies Announced acquisition of Anti-Tuberculosis and Anti-Infectives Portfolio Acquisition of Sanofi’s Select Product Portfolio Note: Acquisition is subject to regulatory approvals Click tAoc qeudisitit iMona osft eArn ttii-tTlueb setryculelosis & Anti-Infectives Portfolio of Sanofi About Key Operating Highlights ▪ GTBL has entered into an agreement with Sanofi (the French-holding company of the Sanofi group) to acquire select product portfolio ▪ Comprehensive Portfolio of Mature brands for the treatment of tuberculosis as well €62 mn 13 as other infections ▪ The portfolio generated €62mn net sales in CY25 and is mostly marketed in Middle Net Revenue (CY25) Portfolio Brands E [Showing first 8,000 characters — download PDF for full document]